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Abstract
Background Endoscopic ampullectomy has been recognized as a safe and reliable means to resect selective tumors of the 
ampulla of Vater and is associated with lower morbidity and mortality rates compared to surgical resection. Success rates 
range from 42 to 92%, with recurrences reported in up to 33%. Studies on endoscopic resection of advanced lesions such as 
those with intraductal extension of adenoma (IEA) and lateral spreading adenomas (LSA) are limited. We aimed to evaluate 
the technical success, complications, and recurrence of endoscopic resection of ampullary adenomas, including advanced 
lesions.
Methods All patients referred to the Erasmus Medical Center for endoscopic resection of an ampullary lesion were retrospec-
tively identified between 2002 and 2016. Endoscopic success was defined as complete excision of the adenoma, irrespective 
of the number of attempts, in the absence of recurrence.
Results We included 87 patients with a median age of 65 years. Of these, 56 patients (64%) had an adenoma confined to 
the ampulla (ACA), 20 patients (23%) had an LSA, and 11 patients (13%) were treated for an IEA. The median lesion sizes 
were 24.6 mm, 41.4 mm, and 16.3 mm, respectively (P < 0.001). Complications occurred in 22 patients (25.3%), of which 
hemorrhage was most prevalent (12.6%), followed by perforation (8.1%). Complications were equally divided (P = 0.874). 
The median follow-up duration was 21.1 months (12–45.9) for ACA, 14.7 months (4.2–34.5) for LSA, and 5.8 months 
(3.7–22.0) for IEA (P = 0.051). Endoscopic resection was curative in 87.5% of patients with an ACA, 85% in patients with 
an LSA, and in only one patient with an IEA (P < 0.001). Recurrence occurred in 10 patients (11.5%) (P = 0.733).
Conclusion Endoscopic ampullectomy is safe and highly successful in selected patients with an adenoma with or without 
lateral spreading. Outcomes of endoscopic treatment adenomas with an intraductal extension are less favorable and in these 
cases surgery should be considered.
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Abbreviations
APC  Argon plasma coagulation
ACA  Adenoma confined to the ampulla
EA  Endoscopic ampullectomy
ERCP  Endoscopic retrograde 
cholangiopancreatography
EUS  Endoscopic ultrasound
IEA  Intraductal extending adenoma
FAP  Familial adenomatous polyposis
HGD  High-grade dysplasia
LGD  Low-grade dysplasia
LSA  Lateral spreading adenoma
NSAIDs  Nonsteroidal inflammatory drugs
Lesions of the ampulla of Vater are relatively rare. Adeno-
mas are the most common benign tumors arising from the 
ampulla even though benign neoplasms account for < 10% of 
all periampullary neoplasms [1]. The detection of ampullary 
adenomas has increased over the last years most likely due 
and Other Interventional Techniques 
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to the more abundant use of esophagogastroduodenoscopy 
and ultrasonography [2]. As in colorectal adenomas, ampul-
lary adenomas can undergo malignant transformation, and 
therefore it is essential to completely remove the lesion [3]. 
Historically ampullary adenomas have been resected surgi-
cally [4, 5]. Over the last decades, endoscopic ampullectomy 
(EA) has been recognized as a safe and reliable alternative 
treatment for selective tumors of the ampulla of Vater [5–7]. 
EA has lower morbidity and mortality rates than surgical 
procedures [3, 8]. Success rates after EA have been reported 
within a wide range from 46 to 92% and are largely based 
on retrospective, heterogeneous case series. Studies have 
shown that multiple procedures may be required to com-
pletely remove adenomatous tissue, in particular for larger 
lesions [9–14]. It is difficult to compare the outcomes of the 
various studies due to the lack of a consistent definition of 
‘success’ and highly variable follow-up length. Additionally, 
the success rate also appears to be dependent on the extent 
of the tumor, i.e., whether it is confined to the ampulla, 
laterally spreading beyond the ampulla over the duodenal 
surface or growing intraductally. The overall complication 
rate of EA is around 15% and mainly consists of bleeding 
and pancreatitis. Recurrence of adenomas is reported in up 
to 33% of the cases, despite supposedly complete removal 
of the tumor at the index procedure [10, 12, 15]. Despite the 
increasing number of studies concerning endoscopic resec-
tion of ampullary tumors, studies reporting on the outcome 
of resection of ampullary adenomas with lateral spreading 
or intraductal extension are limited. There seems to be con-
sensus that every patient with an ampullary tumor should be 
given a chance of endoscopic resection as long as the tumor 
appears benign and tumor size is not a contraindication [9, 
16]. The aim of our study was to evaluate the technical suc-
cess, complications and recurrence of endoscopic resection 
ampullary adenomas, in particular lateral spreading ampul-
lary adenomas and those with intraductal extension.
Materials and methods
We conducted a retrospective study in patients referred to 
the Erasmus MC, University Medical Center Rotterdam 
(Rotterdam, The Netherlands) for endoscopic resection of 
an ampullary adenoma over a 14-year period (between Janu-
ary 2002 and November 2016). All 107 cases were identified 
using an electronic endoscopic database reporting system 
(ENDOBASE, Olympus, Hamburg) searching for the terms 
‘papillary resection’, ‘papillectomy’, ‘ampullectomy’, ‘ade-
noma’, and ‘spreading’. Additionally, a search was done in 
the nationwide network and registry of histo- and cytopa-
thology in the Netherlands (PALGA) to search for patients 
diagnosed with an ampullary adenoma at our institution. 
We identified 87 patients with ampullary tumors that were 
histologically confirmed to be adenomas. Pathology slides 
were not re-examined. Additional inclusion criteria included 
adenomas of both major papilla and minor papilla, without 
invasive cancer on biopsy, and adenomas with substantial 
intraductal extension and adenomas with a lateral spreading 
growth pattern. A lateral spreading adenoma was defined as 
an adenoma of ≥ 10 mm in diameter that extends laterally 
along the surface of the gastrointestinal tract [17]. Patients 
with FAP were included in our study. Non-adenomatous 
tumors of the ampulla of Vater (neuroendocrine neoplasms, 
carcinomas) were excluded. Data that were extracted from 
the electronic patient records included patient demographics, 
clinical presentation, laboratory results, diagnostic findings, 
details on the endoscopic resection, follow-up, and morbid-
ity and mortality.
The decision to perform endoscopic ultrasound (EUS) 
prior to endoscopic retrograde cholangiopancreatography 
(ERCP) was at the discretion of the treating physician and 
endoscopist. In early years not always performed, but EUS 
evaluation has become part of routine work-up during the 
last years. Endoscopic resection was performed using a side-
viewing therapeutic duodenoscope. Procedures were done 
under either conscious sedation, anesthesia administered 
propofol sedation or general anesthesia. Rectal NSAID’s 
were administered during the procedure since 2010 to reduce 
the risk of pancreatitis. The technique of EA is not standard-
ized and dependent on local anatomy, extension and char-
acteristics of the adenoma and personal preference of the 
endoscopist. For snare resection, “ENDO CUT Q” mode was 
used with standard settings for polypectomy: effect 3, cut 
duration 1, cutting interval 6 (VIO200D, ERBE, Tübingen, 
Germany), and standard materials were used, among which 
an oval snare (Acusnare, Cook Medical) and a stiff hexago-
nal snare (Captivator, Boston Scientific, USA). In general, 
in cases without intraductal extension, the first step is can-
nulation of the pancreatic duct to fill the duct (partially) with 
diluted methylene blue to facilitate cannulation of the pan-
creatic duct after resection. In bulky or smaller adenomas in 
which en bloc resection is attempted, the caudal and lateral 
parts of the lesion are lifted with saline. This step is done 
carefully since “over-lifting” can lead to a more difficult 
resection of the ampulla itself. After resection, the specimen 
is retrieved with either the snare or a Roth-net and sent for 
pathological examination. At this stage, procedural bleeds 
are most likely to occur and these can be treated endoscopi-
cally with either adrenalin injection, a coag-grasper or clips. 
Visible residual adenomatous tissue is either resected with 
the snare or treated with argon plasma coagulation (APC). 
The final step of the procedure is cannulation of the pancre-
atic duct and placement of a 4 or 5 french unflanged single 
pigtail endoprosthesis. A plain abdominal film was obtained 
within 2 weeks after the resection to check for spontaneous 
stent migration. If no spontaneous migration had occurred, 
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the stent was removed at gastroscopy. Lateral spreading 
lesions were removed in a piecemeal fashion with con-
tinuous lifting with gelofusine, methylene blue and diluted 
epinephrine (5 ml 1:10,000 in 500 ml gelofusine). In most 
instances, resection was started at the most caudal part of 
the lesion and the ampullary region itself was resected last. 
Resected pieces of the adenoma were positioned in either 
bulb or stomach and retrieved at the end of the procedure. 
In case of intraductal extension, a biliary and/or pancreatic 
sphincterotomy was performed to facilitate removal of intra-
ductal tissue after a balloon sweep of the duct.
The surveillance protocol after treatment consists of a 
repeat examination after 1–6 month (depending on the initial 
success of treatment) followed by repeat examinations every 
3–6 months for 2 years, and yearly thereafter for a total period 
of 5 years. Median follow-up time was calculated in months 
from the initial EA up to the most recent endoscopic examina-
tion or surgical intervention. Endoscopic success was defined 
as complete excision of the adenoma, disregarding the num-
ber of sessions needed, and the absence of recurrence over 
the total follow-up period. It was decided to use endoscopic 
success as an alternative for curative resection, because a R0 
resection is often not acquired and in a number of cases com-
plete removal is achieved in more than one session.
All statistical analyses were performed using SPSS 
21.0 software (IBM Corp: Armonk, NY, USA). Data were 
expressed as mean ± standard deviation, median, and range. 
Statistical analysis included the Chi-square test, Fisher’s 
exact test, and Kruskal–Wallis test with P values < 0.05 
regarded as significant. Survival analysis was demonstrated 
using the Kaplan–Meier method.
Results
Patient demographics and tumor characteristics
A total of 110 patients were treated endoscopically for sus-
pected adenomas of the ampulla of Vater during the 14-year 
study period. Twenty-three cases were excluded from the 
study, because they did not meet the inclusion criteria (car-
cinoma [n = 11], non-availability of the resection specimen 
[n = 7], specimen showing signs of inflammation without 
dysplasia [n = 3], ganglioneuroma [n = 1], neuroendocrine 
tumor [n = 1]). Eventually, 87 patients were included, 60 
patients (69%) with low-grade dysplasia (LGD) and 27 
patients (31%) with high-grade dysplasia (HGD). Based on 
the anatomical extension of the adenoma, the 87 patients 
were divided into three groups: 56 patients had an adenoma 
confined to the ampulla (ACA), 20 patients had a lateral 
spreading ampullary adenoma (LSA), and 11 patients had an 
adenoma with intraductal extension (IEA). A study overview 
is depicted in Fig. 1. Figure 2 illustrates advanced ampullary 
adenomas. Patients demographics are listed in Table 1. A 
total of 45 men and 42 women with a mean age of 65 years 
(range 32–89 years) were included. In 18 patients (20.7%), 
the adenoma was found incidentally or during endoscopic 
examination in case of FAP. The remaining patients had 
symptoms for which medical investigations were initiated: 
abdominal pain in 34 patients (39.1%), anemia in 16 patients 
(18.4%), weight loss in six patients (6.9%), jaundice in four 
patients (4.6%), and pancreatitis in three patients (3.4%). No 
statistical differences were observed among groups. Tumor 
characteristics are listed in Table 2. Seventy-one (81.6%) 
patients underwent biopsy before EA: no dysplasia was seen 
in three patients (3.4%), 44 patients (50.6%) had LGD, and 
24 patients (27.6%) had HGD. Post-ampullectomy histologi-
cal diagnosis confirmed LGD in 60 patients (69%) and HGD 
in 27 patients (31%). The average tumor size was 27.7 mm 
(SD ± 15.9). LSA were significantly larger (41.4  mm, 
SD ± 12.9, P < 0.001).
Endoscopic ampullectomy
Overall, success resection with absence of recurrence was 
achieved in 67 patients (77%); 87.5% for ACA, 85% for lat-
eral spreading adenoma, and only 9.1% in case of intraductal 
extension (P < 0.001). Multiple procedures were required to 
successfully remove the adenoma in three patients with an 
ACA, seven patients with LSA and one patient with an IEA. 
En bloc resection was achieved in 37 patients with an ACA 
(66.1%). Post-ampullectomy APC application to treat rem-
nant adenomatous tissue was applied in 58 patients (66.7%). 
EA was complemented with placement of a pancreatic duct 
stent in 60 patients (68.9%). Eight patients (9.2%) were 
referred for surgery after failed endoscopic resection, of 
whom six with intraductal extension. Of these latter patients, 
the final histopathological diagnosis was LGD (n = 3), HGD 
(n = 2) and invasive carcinoma (n = 1).
Complications
Complications occurred in 22 patients (25.3%). The most 
common complication was post procedural hemorrhage 
(12.6%). Five patients required transfusions and seven 
patients underwent endoscopic management (adrenaline 
injection and/or hemoclip placement). In one patient, bleed-
ing was controlled by coiling the gastroduodenal artery. 
(Retro)peritoneal perforation occurred in seven patients 
(8.1%). One patient developed a pneumothorax for which 
a thorax drain was placed. All other patients were treated 
with antibiotics only. Acute pancreatitis developed in three 
patients (3.4%), mild in two patients and severe in one 
patient. All three patients suffering from post-ERCP pan-
creatitis successfully underwent pancreatic duct stent place-
ment. Cholangitis occurred in only one patient, treated with 
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antibiotics. There was no procedure-related mortality. No 
stenosis of the papilla of Vater was observed in our cohort. 
There were no statistical significant differences in the occur-
rence of complications between groups. Endoscopic success 
rates and complications are shown in Table 3.
Follow‑up and recurrence
The median follow-up period was 18.6  months (IQR 
7.6–39.5 months); 21.1 months in ACA, 14.7 months in 
LSA, and 5.8 months in IEA. Recurrence was observed 
in ten patients (10.7%). Five patients with ACA showed 
recurrence (8.9%), of the 20 patients treated for an LSA, 
four patients showed recurrence (20%). In the IEA only, 
11 patients were endoscopically treated; six patients were 
referred for surgery, and in two patients it was decided to 
discontinue follow-up because of other medical conditions. 
Of the remaining three patients, one developed recurrence of 
the IEA. In only one patient with ACA (1.8%) surgical resec-
tion because of recurrence was required. LSA patients with 
recurrence were all treated endoscopically. The IEA patient 
with recurrence was also referred for surgery. After 2 years 
of follow-up, 93% of patients with an ACA were free from 
recurrence and 90% of patients with an LSA, as depicted in 
Fig. 3. Details are listed in Table 4.
Discussion
This is a retrospective single-center cohort study describing 
the endoscopic management and outcome of patients with 
(advanced) ampullary adenomas. Since the first large cohort 
study in 1993 by Binmoeller et al. [11], various reports have 
been published showing promising results of the endoscopic 
treatment of ampullary adenomas as an alternative for surgi-
cal resection [9, 12, 13, 18–21]. Our data show that EA is 
indeed a safe and effective treatment, also in patients with 
lateral spreading adenomas. In patients with intraductal 
extension however, surgical resection should be considered 
as primary treatment.
Currently, guidelines on the endoscopic or surgical 
management of ampullary adenomas are lacking. Liter-
ature data suggest that surgery is indicated for patients 
with larger lesions, for cases when no skilled interven-
tional endoscopists with experience in ampullectomy are 
available and, obviously, in lesions suspected for malig-
nancy and potential lymph node invasion [18, 22]. Surgical 
options include transduodenal ampullectomy and pancrea-
ticoduodenectomy, but are associated with high morbidity 
and mortality rates. Morbidity rates vary from 4 to even 
68% of patients who underwent pancreaticoduodenectomy 
and mortality is reported up to 7% [23, 24]. With the intro-
duction of EA in 1983 by Suzuki et al. [25], treatment has 
Fig. 1  Study overview
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shifted towards minimal invasive endoscopic resection as 
an alternative to surgery and this shift has been acceler-
ated due to technical improvements in endoscopy over the 
last decades.
The study by Binmoeller et al. [11] included 25 patients 
with ampullary adenomas that were endoscopically treated, 
demonstrating lower morbidity and mortality rates than 
surgical intervention with a success rate of 75%. To date, 
Table 1  Demographics and 
clinical presentation
*Fisher’s Exact test [Exact Sig. (2-sided)]
**Some patients had multiple complaints at clinical presentation
a Data are expressed as mean and standard deviation
Adenoma 









No. of patients, n (%) 56 (64.4%) 20 (23.0%) 11 (12.6%) 87
Male, n (%) 29 (51.8%) 9 (43.9%) 7 (63.6%) 45 (51.7%) 0.610
Mean age (years)a 63.0 (13.3) 64.6 (11.7) 74.7 (10.7) 64.9 (13.1) 0.017
FAP, n (%) 7 (12.5%) 5 (25%) 0 12 (13.8%) 0.139
Presentation, n (%)
 Incidental 5 (8.9%) 2 (10%) 0 7 (8.0%) 0.859*
 FAP follow-up 7 (12.5%) 4 (20%) 0 11 (12.6%) 0.334*
 Biliary-pancreatic symptoms 9 (16.1%) 1 (5%) 2 (18.1%) 12 (13.8%) 0.377*
 Abnormal laboratory results 5 (8.9%) 2 (10%) 2 (18.1%) 9 (10.3%) 0.497*
 Non-specific symptoms 29 (51.8%) 11(55%) 6 (54.5%) 46 (52.9%) 0.948
Clinical symptoms, n (%)**
 Asymptomatic 16 (28.6%) 7 (35%) 2 (18.2%) 25 (28.7%) 0.698
 Jaundice 2 (3.6%) 0 2 (18.2%) 4 (4.6%) 0.108*
 Abdominal pain 22 (39.3%) 6 (30%) 6 (54.5%) 34 (39.1%) 0.290
 GI bleeding 6 (10.7%) 1 (5.0%) 0 7 (8.0%) 0.595*
 Anemia 8 (14.3%) 7 (35%) 1 (9.1%) 16 (18.4%) 0.126*
 Pancreatitis 3 (5.4%) 0 0 3 (3.4%) 0.700
 Cholangitis 2 (3.6%) 0 1 (9.1%) 3 (3.4%) 0.439*
 Cholecystitis 2 (3.6%) 0 0 2 (2.3%) 1.000*
 Weight loss 4 (7.1%) 1 (5.0%) 1 (9.1%) 6 (6.9%) 1.000*
Table 2  Tumor characteristics
*Fisher’s Exact test [Exact Sig. (2-sided)]
a Data are expressed as mean and standard deviation
Adenoma 














Pre-resection biopsy, n (%) 45 (80.4%) 16 (80%) 10 (90.9%) 71 (81.6%) 0.841*
 No dysplasia 3 (5.4%) 0 0 3 (3.4%) 0.737*
 LGD 28 (50%) 11 (55%) 5 (45.5%) 44 (50.6%) 0.737*
 HGD 14 (25%) 5 (25%) 5 (45.5%) 24 (27.6%) 0.737*
EUS assessment, n (%) 47 (83.9%) 13 (65%) 11 (100%) 71 (81.6%) 0.047*
Type of resection, n (%)
 En bloc 37 (66.1%) 1 (5.0%) 3 (27.3%) 41 (47.1%) < 0.001
 Piecemeal 18 (32.1%) 16 (80%) 8 (72.7%) 42 (48.3%) < 0.001
Tumor size, in  mma 24.6 (15.1) 41.4 (12.9) 16.3 (4.3) 27.7 (15.9) < 0.001
Histology resection specimen, n (%)
 LGD 39 (69.6%) 13 (65.0%) 8 (72.7%) 60 (69.0%) 0.835
 HGD 17 (30.4%) 7 (35.0%) 3 (27.3%) 27 (31.0%) 0.835
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outcome data of EA are largely based on retrospective case 
series in which success is reported in the range of 46–92% 
[9–14]. This wide range is explained by differences in selec-
tion criteria, tumor size, extent of the tumor, and probably 
of key importance, the experience of the endoscopist. In our 
study, the overall success rate of endoscopic resection was 
77%. Categorization of adenomas based on the extent of the 
tumor, however, showed a significant difference in success 
rates. The success rate in patients with an adenoma confined 
to the ampulla and patients with a lateral spreading adenoma 
is excellent, 87.5% and 85%, respectively. In contrast, how-
ever, the endoscopic management of patients with an IEA was 
Fig. 2  Overview of advanced ampullary adenomas. A LSA. B Intraductal extended adenoma with extension in the common bile duct. C Radial 
EUS image of the intraductal extended adenoma depicted in B 
Table 3  Endoscopic 
success and post-procedural 
complications
*Fisher’s Exact test [Exact Sig. (2-sided)]
Adenoma 














Endoscopic success, n (%) 49 (87.5%) 17 (85.0%) 1 (9.1%) 67 (77.0%) < 0.001*
Referral to surgery after 
failed ER, n (%)
1 (1.8%) 1 (5%) 6 (54.5%) 8 (9.2%) < 0.001*
Complications, n (%) 15 (26.8%) 4 (20.0%) 4 (36.4%) 23 (26.4%) 0.630
 Bleeding 8 (14.3%) 2 (10.0%) 1 (9.1%) 11 (12.6%) 0.823
 Perforation 3(5.4%) 2 (10.0%) 2 (18.2%) 7 (8.1%) 0.337
 Pancreatitis 3 (5.4%) 0 0 3 (3.4%) 0.423
 Cholangitis 1 (1.8%) 0 0 1 (1.1%) 0.756
 Papillary stenosis 0 0 0 0 –
Table 4  Follow-up and 
recurrence
*Fisher’s Exact test [Exact Sig. (2-sided)]
a Data are expressed as median and interquartile range
Adenoma 























Recurrence, n (%) 5 (8.9%) 4 (20%) 1 (9.1%) 10 (11.5%) 0.305*









93% 90% 0% – –
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much less favorable with complete removal of the adenoma 
in 1 out of 11 patients only. Extension into the biliary duct or 
pancreatic duct of an ampullary adenoma has been historically 
regarded as a contraindication of endoscopic management 
[12, 13, 19, 26]. Therefore, studies evaluating the endoscopic 
management of IEAs are rare and mostly based on small 
groups. Bohnacker et al. [20] reported a success rate of 46% 
in 31 patients endoscopically treated for an IEA. The authors 
could not identify criteria predicting a successful resection 
and postulate that limited intraductal involvement allows for 
a reasonable attempt of endoscopic management, provided 
by experienced endoscopists. Cheng et al. [10] treated two 
patients with IEA endoscopically of which one was lost to 
follow-up and one showed no recurrence at 1-year follow-
up. The optimal treatment strategy in patients with ampullary 
adenomas with intraductal extension remains elusive. Ideally, 
after appropriate ampullary resection and sphincterotomy, the 
intraductal extension of the adenomatous lesion is exposed, 
visually inspected, and removed. The role of radiofrequency 
ablation to treat intraductal extension of ampullary adeno-
mas is currently under investigation and shows some promise 
[27, 28]. Needless to state that adequate follow-up is pivotal 
importance in order to timely revert to surgical resection not 
losing out on an opportunity for curative treatment.
Even though various studies have confirmed a decrease 
in procedure-related complications for endoscopic man-
agement of ampullary adenomas in comparison to surgical 
resection, complication rates are described up to 33% and 
remain as an important concern [10, 12, 15]. Catalano et al. 
[12] performed a large study combining the results of EA 
from four pancreaticobiliary endoscopy centers, including 
103 patients with a success rate of 80% and a complication 
rate of 10%. In 2013, Onkendi et al. [8] published the results 
of a large comparative study of the outcomes of operative 
and endoscopic resection showing post-endoscopic compli-
cations in 29% of treated patients. Procedure-related com-
plications in our cohort, including mainly bleeding, perfora-
tions and pancreatitis, occurred in 25.3% of patients with no 
statistical between groups.
Post EA bleeding was seen most often in our cohort 
(12.6%), with literature data indicating a median risk of 
8.5% of cases [29]. Most patients were treated endoscopi-
cally, but one patient required coiling of the gastroduodenal 
artery to control the bleed. Although the IEAs and adenomas 
with a lateral growth pattern are reported to be associated 
with a higher bleeding risk, we did not observe this in our 
series [15, 20, 30].
Post-ERCP pancreatitis is the most common complication 
after EA, with an incidence reported between 8 and 19% 
[10, 12, 20, 30, 31]. Pancreatic stent placement during the 
procedure may reduce the risk of this complication [9, 20, 
32, 33], as well as administration of nonsteroidal inflam-
matory drugs (NSAIDs) [34]. Previous studies reported a 
success rate of pancreatic stent placement in patients with 
an ampullary adenoma of 4–92% [11, 12, 35]. In the present 
study, pancreatic stent placement was successful in 69% of 
patients. Post-ERCP pancreatitis was diagnosed in only 3.4% 
of patients. Administration of rectal NSAIDs has become 
standard practice at our unit since 2010, in accordance with 
the ESGE guideline [36]. All three patients that suffered 
from post-ERCP pancreatitis in our series had undergone 
prophylactic pancreatic duct stent placement.
Perforation occurred in seven patients (8.1%). There were 
no statistical differences among groups (P = 0.337), how-
ever, as expected, our data indicate that perforation occurred 
more in the advanced adenoma groups. The incidence of 
perforation is higher in our cohort compared to previous 
series; however, patients were successfully managed with 
conservative treatment.
Papillary stenosis is a known late complication of EA 
with an incidence of 2.9–8%. No cases of papillary stenosis 
were reported in our cohort.
The median follow-up of patients with an ampullary ade-
noma treated endoscopically reported in literature ranges 
from 9 to 66 months with recurrence described up to 33% 
of cases [10, 12, 19, 20]. In our study, the median follow-up 
duration was 18.6 months. No clear guidance regarding the 
appropriate length of endoscopic follow-up is available, but 
several studies indicate a period of at least 2 years [9–12]. In 
the present study, recurrence occurred in 11.5% of patients 
after a median of 13.1 months (IQR 4.6–33.1), but in one 
case recurrence was found 55 months after initial therapy.
There are several potential limitations to our study. The 
retrospective nature makes this study prone to selection and 
recall bias. However, due to the rarity of this condition a 
prospective study is unlikely to be carried out. Also, the 
number of patients in the advanced adenoma groups was 
Fig. 3  Recurrence-free survival according to endoscopic resection 
and extension of the adenoma
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small making statistical comparisons between groups of 
limited value.
In conclusion, this single-center retrospective cohort 
study confirms that EA can be a safe and successful treat-
ment modality for patients with an ampullary adenoma 
confined to the ampulla, but also for patients with a lat-
eral spreading papillary adenoma. Meticulous endoscopic 
follow-up to detect and treat recurrence is pivotal. In case 
of intraductal extension of adenomatous tissue, endoscopic 
success rates are reduced to such a level that surgical resec-
tion should be considered.
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